Alkem Laboratories Revenue History — Quarter by Quarter

Alkem Laboratories's revenue moved from ₹3,374 Cr in Q3 FY25 to ₹3,737 Cr in Q3 FY26, a 10.7% change over 5 quarters. The table keeps each quarter linked back to the underlying earnings page.

Revenue by Quarter

Quarter	Revenue (₹ Cr)	YoY Change
Q3 FY26	₹3,737 Cr	+10.7%
Q2 FY26	₹4,001 Cr	+17.2%
Q1 FY26	₹3,371 Cr	+11.2%
Q4 FY25	₹3,144 Cr	+7.1%
Q3 FY25	₹3,374 Cr	+1.5%

What management said about revenue

Q3 FY26 · Domestic business to grow 100-150 bps above IPM

Management expects domestic business to continue growing 100-150 basis points above the Indian pharmaceutical market growth rate.

Q3 FY26 · Occlutech revenue CAGR of 14% over 5 years

Occlutech is expected to grow at a 14% CAGR over the next five years from existing products, excluding new product launches.

Q2 FY26 · India business to outperform IPM by 100-150 bps

Management expects India growth to continue at double-digit, outperforming IPM by 100-150 bps in H2 FY26 and FY27.

Q2 FY26 · US business to deliver low double-digit growth in FY26

US growth expected to be ~10-11% for FY26, driven by new launches including Sacubitril/Valsartan.

Q2 FY26 · US CDMO plant to reach INR 300 crore annual run rate in 12-18 months

The US CDMO plant is expected to achieve an annual revenue run rate of INR 300 crore within 12-18 months of operations.

Q1 FY26 · India business to grow 100-250 bps faster than IPM

Management expects India business to continue outperforming the IPM by 100-250 basis points, with IPM growth assumed at 8-9%.

Q1 FY26 · U.S. business mid-to-high single digit growth expected

U.S. business is expected to grow mid-to-high single digit in FY26, subject to tariff and pricing trends.

Q4 FY25 · US business mid-single-digit growth in FY26

US revenue is expected to grow at a mid-single-digit rate in FY26, driven by 5-6 new product launches and improved supply.

Q4 FY25 · Domestic business to outperform IPM by 100 bps in FY26

India business is expected to grow at least 100 basis points above the IPM growth rate of 7-8%.

Q3 FY25 · Domestic business to grow in line with IPM (~7%) for FY25

Q4 implied growth of ~9.5-10% driven by strong secondary optics and low base.

Q3 FY25 · US business expected to be flat YoY in Q4

Improved from -22% in Q2 to -7% in Q3; supply normalization should lead to neutral growth by Q4.

Q2 FY25 · Domestic revenue growth of 8-9% for FY25

Management maintains full-year domestic growth guidance of 8-9%, with Q4 expected to be particularly strong.